A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease

Warren Olanow, C.; Fahn, Stanley; D. Muenter, Manfred; L. Klawans, Harold; I. Hurtig, Howard; Stern, Matthew; Shoulson, Ira; Kurlan, Roger; David Grimes, J.; Jankovic, Joseph; M. Hoehn, Margaret; H. Markham, Charles; Duvisin, R.; M. Reinmuth, O.; A. Leonard, Hubert; Ahlskog, Eric; Feldman, Robert; A. Hershey, Linda; D. Yahr, Melvin

doi:10.1002/mds.870090107

Public

A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease

Published in Movement Disorders • Jan 1, 1994

Authors:

C. Warren Olanow

Stanley Fahn

Manfred D. Muenter

Abstract

Three hundred and seventy-six subjects with advanced Parkinson's disease participated in a prospective, double-blind placebo-controlled study of the dopamine agonist pergolide mesylate as an adjunct to Sinemet. At 6 months, patients randomized to pergolide had a statistically significant improvement...

Subject

Pergolide

Levodopa

Parkinson's disease

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!